NAC (N-Acetyl-Cysteine) is an antioxidant supplement that looks promising but not definitive for PCOS. The best evidence suggests it may support ovulation and fertility in some treatment settings and may help some metabolic markers, but it is not a proven fix for every PCOS symptom.
NAC is an antioxidant supplement that looks promising but not definitive for PCOS. The best evidence suggests it may support ovulation and fertility in some treatment settings and may help some metabolic markers, but it is not a proven fix for every PCOS symptom.
NAC stands for N-acetyl-cysteine. It is a form of cysteine, an amino acid building block, and is often described as an antioxidant support supplement because it helps the body make glutathione, one of its main internal antioxidants. In PCOS research, NAC is thought to matter because oxidative stress, insulin resistance, and hormone disruption can overlap. That gives NAC a plausible mechanism for supporting metabolic function and possibly ovulation-related pathways, but plausible mechanism is not the same as guaranteed clinical benefit.
Most PCOS studies used around 1.2–1.8 g daily, often split into 2 or 3 doses. In practice, that usually means taking NAC with meals if needed for tolerance. A product that delivers the intended daily dose without requiring a very high capsule count is usually more realistic for long-term adherence. Because the strongest evidence is in specific fertility or metabolic contexts, it makes sense to use NAC with a clear goal in mind rather than taking it casually “just in case.”
NAC is often described as reasonably well tolerated, but the PCOS evidence base is still not strong enough to treat it as risk-free or automatically appropriate for everyone. The most practical concern is tolerability, especially digestive side effects. For women who are trying to conceive, pregnant, or breastfeeding, the safest editorial position is to avoid casual use without clinician input, because the PCOS evidence supports promise rather than certainty.
Across 22 studies, NAC improved progesterone and endometrial thickness, and increased LH versus metformin. It did not clearly improve estradiol, SHBG, or FSH overall.
NAC reduced total testosterone and increased FSH, with possible oestrogen benefit after bias adjustment. It did not clearly improve LH, SHBG, follicles, endometrial thickness, or progesterone.
NAC lowered fasting glucose versus placebo or metformin, and reduced total cholesterol versus placebo. Effects on insulin, BMI, weight, TG, and LDL were not clearly superior.
NAC and L-carnitine produced similar pregnancy and ovulation rates, but NAC improved free testosterone and insulin resistance markers more.
In infertile women with PCOS, NAC added to letrozole increased mature follicles, ovulation, and pregnancy rates, with no major adverse effects reported.
In PCOS patients undergoing IUI, NAC did not significantly improve pregnancy rate, mature follicles, or endometrial thickness.
Adding NAC to clomiphene improved mature follicles, endometrial thickness, ovulation, and pregnancy rates versus placebo in infertile women with PCOS.
In CC-resistant PCOS, metformin plus clomiphene outperformed NAC plus clomiphene for ovulation and pregnancy over 3 months.
In CC-resistant PCOS, NAC plus clomiphene improved ovulation and pregnancy versus placebo, with no OHSS reported in the NAC group.
NAC has a plausible metabolic role in PCOS because of its antioxidant and glutathione-related actions, and some of the clinical data support that idea. A recent metabolic meta-analysis found that NAC lowered fasting glucose, with some signal for total cholesterol as well.
However, the same evidence did not show clear superiority for many other metabolic outcomes such as weight, BMI, triglycerides, or LDL. So it may be relevant for insulin-resistance support, but it is not the strongest or most universally supported option in this space.
This is one of the strongest reasons people look into NAC for PCOS. Several trials and meta-analyses suggest NAC may improve ovulation-related outcomes, especially in women being treated for infertility rather than in a general PCOS population.
That said, the results are not uniform. Some studies are positive, while others are neutral, and the effect seems to depend on the treatment setting and comparator. That is why NAC is better described as a supportive option rather than a reliably effective ovulation supplement for everyone with PCOS.
This is a common search question, but the answer needs nuance. Some trials and pooled analyses suggest NAC can perform well against placebo and may look helpful for selected outcomes, but that does not mean it is generally better than metformin.
In fact, one randomized trial in clomiphene-resistant PCOS found metformin plus clomiphene outperformed NAC plus clomiphene for ovulation and pregnancy outcomes. That makes it unsafe to position NAC as a superior substitute. At most, it may be a useful adjunct or an option for selected cases.
The fertility angle is where NAC has some of its most interesting PCOS data. Positive trials suggest NAC may improve pregnancy-related outcomes when added to ovulation-induction treatment in some women with PCOS, especially in clomiphene-resistant infertility.
But the evidence is still mixed. Not every study is positive, and one head-to-head trial found metformin plus clomiphene performed better than NAC plus clomiphene. For that reason, NAC is better seen as a possible adjunct rather than a replacement for established fertility care.
Evidence-led, supportive PCOS guidance - without pressure or perfection.
Information on this site is for educational purposes only and is not a substitute for medical advice.